Coenzyme Q10 is a fat-soluble compound your body makes to help nearly every cell produce energy, and one of the most popular supplements in the world. Its evidence is narrower than its reputation. The strongest signal is in chronic heart failure, with a modest, repeatable effect on preventing migraine.
The muscle-ache use that filled millions of medicine cabinets is not supported by the better trials. It also does not reliably lower blood pressure. It is inexpensive and causes few side effects, so pick it for a specific reason.
Findings & Outcomes
What It Is
Your body builds coenzyme Q10 in nearly every cell, a fat-soluble molecule the mitochondria use to turn food into usable energy. It also works as an antioxidant. Your own production covers most of what you need, and small amounts come from meat and fish. Levels fall with age and run lower in some heart diseases. That is where most of the useful research sits. As a supplement it costs little, though it absorbs poorly unless a meal supplies some fat.
Anatomy of the Practice
1Inside the mitochondria
CoQ10 shuttles electrons along the respiratory chain, the step where cells turn food and oxygen into ATP. The tissues that burn the most energy, the heart above all, hold the most CoQ10. The clearest clinical signal is in heart failure, where the muscle's own stores run low.
2As an antioxidant
In its reduced form, ubiquinol, CoQ10 also neutralizes free radicals in cell membranes and helps regenerate vitamin E. This mechanism is the one most often invoked for its broader claims, and the chemistry holds. A reaction in a cell is not the same as a measured benefit in a person.
3The statin connection
Statins block the same early pathway the body uses to build both cholesterol and CoQ10, so they lower circulating CoQ10 as a side effect. That fact is the basis of the muscle-ache theory: if statins lower CoQ10 and cause muscle symptoms, replacing it should help.
What It Does
The evidence for CoQ10 is uneven. Two settings hold up, the popular muscle-ache use does not, and a separate use touches male fertility.
The best evidence is chronic heart failure. A two-year randomized trial found that adding CoQ10 to standard treatment lowered the rate of serious cardiac events and death. Pooling the heart-failure trials points the same way on survival. The result rests on one moderate-sized trial and has not been replicated at scale. The trial enrolled diagnosed heart-failure patients only, so it says nothing about a healthy heart.
Migraine prevention is the second setting. CoQ10 modestly cuts how often attacks come and shortens them. The attacks that still occur are no less severe.
In every trial that found a benefit, CoQ10 was added on top of standard treatment, never used instead of it.
The muscle-ache use is the popular one. Replacing the CoQ10 statins deplete does not relieve the pain. A tightly run trial in patients with blind-confirmed statin muscle pain found no benefit over placebo, even after CoQ10 raised blood levels sharply. That trial documented a nocebo response: tested blind, most people who blamed their statin felt the same ache on a dummy pill as on the drug. Some earlier, broader analyses did report a benefit, so the literature is split, but the trials designed around the muscle question show no effect.
A separate use is male subfertility. Pooling three randomized trials in 296 men with poor semen quality, CoQ10 raised sperm concentration and motility compared with placebo. Across those short trials, though, pregnancy rates did not rise and none recorded a live birth, the outcome couples actually want.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Pain
Statin muscle pain: the symptom-focused trials found no benefit, though a broader analysis reported one
This is the reason most people take CoQ10, and the trials designed to test it come up split. The analysis focused on statin muscle pain found CoQ10 was no better than a placebo, while an earlier, broader one found it helped. The muscle-focused trials lean toward no effect.
Kennedy 2020 restricted its pooling to randomized trials of CoQ10 versus placebo in patients with statin-associated myalgia, and found a weighted mean difference of -0.42 on the pain scale (95% CI -1.47 to 0.62, spanning zero) across 7 trials and 321 patients, with no effect on statin continuation (RR 0.99, 95% CI 0.81 to 1.20). Only two of its included studies showed a positive effect. Qu 2018, pooling 12 trials and 575 patients with a broader inclusion, reported reductions in muscle pain, weakness, cramp and tiredness but no change in creatine kinase. The disagreement traces to which trials each analysis admitted; the analysis built around the exact symptom question is the null one.
Who this may not transfer to:The pooled statin trials enrolled both sexes but the analyzes do not report the muscle-pain effect separately by sex, so any sex difference in response is unknown.
The studies · 2
Kennedy et al., effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis · Atherosclerosis 2020;299:1-8
Qu et al., effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials · J Am Heart Assoc 2018;7(19):e009835
In confirmed statin myalgia, CoQ10 did nothing for pain in 41 patients despite four-fold higher blood levels
In the trial that first confirmed people's statin muscle pain was real by testing it blind, adding CoQ10 did nothing for the pain even though it raised blood levels sharply. It also showed that most people who blamed their statin did not actually reproduce the pain on a blind test.
Taylor 2015 first ran 120 patients with prior statin myalgia through a blind crossover of simvastatin versus placebo; only 41 (about 36%) reproduced muscle pain on the statin but not the placebo. Those 41 were then randomized to simvastatin plus CoQ10 (600 mg/day ubiquinol) or simvastatin plus placebo for 8 weeks. Serum CoQ10 rose from 1.3 to 5.2 mcg/mL on supplementation, yet Brief Pain Inventory severity and interference scores rose with simvastatin regardless of CoQ10 assignment (p = 0.53 and 0.56), with no change in muscle strength or VO2max. A crossover of 24 subjects to the alternate arm showed the same lack of effect. The trial is small but tightly designed, and its confirmation step is what gives the null result weight.
Who this may not transfer to:The trial does not report the sex split of the 41 randomized patients, so how the null result divides between men and women is unknown.
The study · 1
Taylor et al., a randomized trial of coenzyme Q10 in patients with confirmed statin myopathy · Atherosclerosis 2015;238(2):329-335
Heart And Vascular
Q-SYMBIO: CoQ10 cut major heart-failure events to 15% from 26% and deaths to 10% from 18%
This is CoQ10's strongest result. In people with moderate to severe heart failure, adding it to their normal treatment for two years roughly halved the rate of serious heart events and lowered the death rate. It was added on top of standard care, not used instead of it.
The Q-SYMBIO trial (Mortensen 2014) randomized 420 patients with moderate to severe chronic heart failure to CoQ10 100 mg three times daily or placebo alongside standard therapy for two years. The short-term endpoints at 16 weeks (NYHA class, 6-minute walk, NT-proBNP) did not differ. The long-term primary endpoint, time to first major adverse cardiovascular event, was reached by 15% on CoQ10 versus 26% on placebo (HR 0.50; 95% CI 0.32 to 0.80; p = 0.003), with significantly lower cardiovascular mortality (9% vs 16%), all-cause mortality (10% vs 18%) and heart-failure hospital stays. It is a single multicenter trial of moderate size; earlier CoQ10 heart-failure trials were underpowered for hard endpoints, and this result awaits replication at similar scale before it changes standard practice.
Who this may not transfer to:Like most heart-failure trials the population was predominantly male, so the size of the benefit specifically in women is less certain.
The study · 1
Mortensen et al., the effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial · JACC Heart Fail 2014;2(6):641-649
Pooled across 14 trials, CoQ10 lowered heart-failure mortality (RR 0.69)
Pulling together all the heart-failure trials points the same way as the big one: people who took CoQ10 were less likely to die over the study periods. The pooled trials agreed closely with each other on this.
Lei 2017 pooled 14 randomized controlled trials with 2,149 heart-failure patients and found CoQ10 reduced mortality versus placebo (RR 0.69; 95% CI 0.50 to 0.95; p = 0.02) with no statistical heterogeneity (I2 = 0%). This aligns with the Q-SYMBIO trial and strengthens the survival signal beyond a single study. The pooled trials vary in size, dose and era, and the mortality benefit rests heavily on the larger contributors, so the pooling supports, not independently proves the effect.
Who this may not transfer to:The pooled heart-failure trials do not report mortality separately by sex, and this literature skews male, so the effect size in women is less certain.
The study · 1
Lei & Liu, efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials · BMC Cardiovasc Disord 2017;17(1):196
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
No meaningful blood-pressure lowering: systolic -3.68 and diastolic -2.03 mmHg, both non-significant
An earlier review suggested CoQ10 lowered blood pressure noticeably, which is where the reputation came from. A later, stricter review that kept only the soundest trials found no meaningful change. If lowering blood pressure is the goal, this is not the tool.
Ho 2016 (Cochrane) updated an earlier review, excluding a trial judged at unacceptably high risk of bias and pooling the two remaining randomized trials (50 participants). CoQ10 did not significantly change systolic BP (-3.68 mmHg; 95% CI -8.86 to 1.49) or diastolic BP (-2.03 mmHg; 95% CI -4.86 to 0.81). The authors graded the evidence moderate-quality and concluded CoQ10 does not have a clinically significant effect on blood pressure, while noting the small number of participants and calling for more trials. This corrects a more optimistic earlier picture from broader reviews that included weaker studies.
Who this may not transfer to:The two pooled hypertension trials are small and do not report the blood-pressure effect by sex, so no sex-specific estimate is available.
The study · 1
Ho, Li & Wright, blood pressure lowering efficacy of coenzyme Q10 for primary hypertension · Cochrane Database Syst Rev 2016;3(3):CD007435
CoQ10 improved exercise capacity in heart failure (SMD 0.62), but not ejection fraction or NYHA class
Beyond survival, people on CoQ10 could exercise somewhat better than those on placebo. But two other measures of how well the heart was working, its pumping fraction and the functional class doctors assign, did not clearly improve.
Lei 2017 reported that CoQ10 improved exercise capacity versus placebo (SMD 0.62; 95% CI 0.02 to 1.12) but found no significant between-group difference in left ventricular ejection fraction (I2 54%) or in NYHA classification (I2 89%), both carrying high heterogeneity. The survival and exercise-capacity signals are more consistent than the direct pump-function measures, so CoQ10 reads as a helpful add-on that does not visibly remodel the failing heart. The high heterogeneity on the functional endpoints is a reason to hold this at emerging strength.
Who this may not transfer to:The pooled functional outcomes are not reported by sex, and the heart-failure trial base skews male, so response in women is less certain.
The study · 1
Lei & Liu, efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials · BMC Cardiovasc Disord 2017;17(1):196
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Fertility
Across 3 trials in 296 subfertile men, CoQ10 raised sperm concentration and motility, but not pregnancy or live birth
Pooling three trials in men with poor semen quality, CoQ10 improved sperm concentration and motility against placebo. The limit is what it did not change: pregnancy rates did not rise, and none of the trials recorded live births. So CoQ10 moves the numbers on a semen analysis, on a small body of short trials, and the outcome couples are after did not follow.
Lafuente 2013 pooled 3 randomized placebo-controlled trials of oral CoQ10 in subfertile men, 149 on CoQ10 and 147 on placebo. Supplementation significantly increased seminal CoQ10 concentration, sperm concentration and sperm motility, but none of the included trials reported live births, and the pooled data showed no increase in pregnancy rates. The evidence base is small and the trials were short, and the analysis measures semen-analysis surrogates, not the birth of a child, so the case is for improved sperm parameters and not for higher fertility. Later fertility reviews reach the same split conclusion.
Who this may not transfer to:The trials enrolled only subfertile men and measured sperm parameters, so the finding is male-specific and does not transfer to women.
The study · 1
Lafuente et al., Coenzyme Q10 and male infertility: a meta-analysis · J Assist Reprod Genet 2013;30(9):1147-1156
Headache And Migraine
Across 5 trials, CoQ10 cut migraine frequency by about 1.52 attacks a month, with severity unchanged
For preventing migraine, CoQ10 modestly cut how often attacks happened, by roughly one and a half fewer per month, and shortened them a little. It did not clearly make the attacks that did occur less severe.
Sazali 2021 pooled 6 randomized trials with 371 adult migraine patients overall. The frequency reduction (MD -1.52; 95% CI -2.40 to -0.65) came from 5 of those trials in 259 participants, while the duration reduction (MD -0.19; 95% CI -0.27 to -0.11) drew on all 6; both showed no heterogeneity (I2 = 0%), and the effect on severity was not statistically significant. The trials are small and use varied doses and co-treatments, and crossover designs were excluded, so the evidence base is limited even though the frequency and duration effects were consistent. CoQ10 is one of several nutraceuticals studied for migraine prevention and sits among the better-tolerated options.
Who this may not transfer to:Migraine populations skew female and the pooled trials do not report the effect separately by sex, so the men-specific estimate is less certain.
The study · 1
Sazali et al., coenzyme Q10 supplementation for prophylaxis in adult patients with migraine: a meta-analysis · BMJ Open 2021;11(1):e039358
How it works
Ubiquinol was not reliably better absorbed than ubiquinone (1.7-fold, not significant)
Ubiquinol is sold as the far better-absorbed form, but in a head-to-head test it was not reliably better than the cheaper ubiquinone. What mattered more was the formulation, and the body ended up with CoQ10 in the same form in the blood either way.
Pravst 2020 ran a randomized three-period crossover in 21 healthy adults aged 65 to 74, comparing single 100 mg doses of a water-soluble syrup, ubiquinol capsules and ubiquinone capsules, tracking plasma CoQ10 over 48 hours. Against the ubiquinone standard, the water-soluble syrup was 2.4-fold more bioavailable (95% CI 1.3 to 4.5, p = 0.002), while ubiquinol was only 1.7-fold and not statistically significant (95% CI 0.9 to 3.1, p = 0.129). The redox status in the blood did not differ by formulation: CoQ10 appeared mostly as ubiquinol even when consumed as ubiquinone, because the body interconverts the two. This is a single-dose pharmacokinetic study, so it speaks to absorption, not to any health outcome.
Who this may not transfer to:This single-dose absorption study enrolled predominantly women and does not test for sex differences, so whether men and women absorb the forms differently is unknown here.
The study · 1
Pravst et al., comparative bioavailability of different coenzyme Q10 formulations in healthy elderly individuals · Nutrients 2020;12(3):784
Formulation and fat drive CoQ10 absorption, with oil-based soft-gels absorbing best
How well CoQ10 absorbs depends mostly on how it is made and what it is taken with. Oil-based soft-gels beat dry formats, and taking it with fat helps, because CoQ10 is fat-soluble. The form on the label matters less than these.
Lopez-Lluch 2019 tested seven different 100 mg CoQ10 formulations in 14 young healthy adults in a double-blind crossover with at least four weeks between doses, measuring plasma CoQ10 area under the curve over 48 hours. Bioavailability differed significantly across formulations; the two best were soft-gel capsules of ubiquinone or ubiquinol, and the dissolving matrix, added preservatives such as vitamin C, and solubilization all affected uptake. Individual variation was large, with some participants absorbing far more than others from the same product, pointing to unidentified physiological factors. Because CoQ10 is fat-soluble, taking it with a meal containing fat and choosing an oil-based soft-gel are the practical levers this supports.
Who this may not transfer to:The absorption study does not report results by sex, so any sex difference in how formulation affects uptake is unknown.
The study · 1
Lopez-Lluch et al., bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization · Nutrition 2019;57:133-140
How It Works
The proposed mechanism is energy. CoQ10 is a required part of how mitochondria make ATP. The reasoning runs that more of it means more cellular energy, above all in the tissues that work hardest.
That reasoning holds up best where a tissue's own stores run low. In the research, that means the failing heart. When heart-muscle CoQ10 runs low, as in heart failure, restoring it plausibly helps the pump, and it is the one setting the clinical evidence supports. The case is weaker where a tissue's stores are already normal. A healthy person with normal stores has no shortage to correct.
How to Take It
A few simple choices decide how well CoQ10 works and what to look for on the label.
Ways to Do It
An oil-based soft-gel taken with a meal is the form that absorbs best. Match it to a reason: heart failure, migraine prevention, or a personal test after statin muscle aches. It is not a substitute for a statin or any prescribed heart medicine.
CoQ10 barely absorbs on an empty stomach. Take it with a meal that has some fat, when uptake into the blood is highest. Around 100 mg a day is the common maintenance dose. The heart-failure trial that found benefit used 300 mg a day, split into three doses, in people with diagnosed heart failure on standard treatment.
Absorption per dose is limited, so a large single serving is partly wasted. For a 200-300 mg dose (migraine or heart failure), split it into two or three servings with meals. More reaches your blood that way than from one large dose.
Ubiquinol, the reduced form, is sold as far better absorbed than ordinary ubiquinone. Head-to-head studies in people show no reliable advantage. The body converts freely between the two forms, and CoQ10 turns up in the blood mostly as ubiquinol whichever you swallow. What moves absorption is the formulation, an oil-based soft-gel over a dry powder.
Three groups have the best case. First, people with diagnosed heart failure working with their cardiologist. Second, people trying to prevent migraine. Third, anyone who quit a statin over muscle aches and wants a personal test.
The molecule is the same across brands; what differs is verification. An oil-based soft-gel from any brand carrying an independent testing mark, such as NSF Certified for Sport or USP, is one practical choice. That mark is what tells you the capsule holds the labeled dose.
Go Deeper
- Hypertension: the blood-pressure levers with stronger evidence than CoQ10.
- Omega-3 fish oil: the other popular heart-and-brain supplement.
- Whole foods: the diet that supplies CoQ10 along with much else.
The Chinese Medicine View
Coenzyme Q10 was first isolated in the 1950s, so it sits entirely outside the classical Chinese materia medica. It has no traditional entry, no channel it enters, and no flavor or temperature assigned by any historical text.
The Heart, in Chinese medicine, governs the circulation and houses the Shen. Its steady function depends on sufficient Qi and Blood to keep the vessels full and moving. CoQ10's one clear clinical effect supports a failing heart muscle that lacks the compound it needs to make energy. That resembles the tradition's concern for a Heart short of the resource to do its work, a loose resonance and no more.
A practitioner would not prescribe CoQ10 as a Heart tonic in any classical sense.
Cautions For This Practice
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Statins measurably lower circulating CoQ10, by a pooled -2.12 across 12 trials
Qu 2018 (Eur J Med Res) pooled 12 randomized trials with 1,776 participants and found statins reduced circulating CoQ10 with a standardized mean difference of -2.12 (95% CI -3.40 to -0.84, p = 0.001). Subgroup analysis showed both lipophilic (SMD -1.91) and hydrophilic (SMD -2.36) statins lowered it, with no significant difference between them and no association with treatment duration. The mechanism is shared: statins inhibit HMG-CoA reductase, an early step the body uses to build both cholesterol and CoQ10. The depletion is well established; its clinical meaning, whether it drives muscle symptoms, is what the myalgia trials test separately and do not settle in CoQ10's favor.Qu et al., the effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials
Well tolerated with no serious harms; observed safe level about 1200 mg a day
Hidaka 2008 reviewed animal and human safety data for CoQ10. A 52-week rat toxicity study gave a no-observed-adverse-effect level of 1200 mg/kg/day, and human clinical-trial data supported an observed safe level of 1200 mg/day for a person. Reported adverse effects in humans were mild and mostly gastrointestinal (nausea, upset stomach, loose stools), clustering at higher doses. Supplemental CoQ10 did not suppress the body's own synthesis and did not accumulate in plasma or tissue after stopping. Typical maintenance doses of 100 to 300 mg/day sit far below the observed safe level, which is why the supplement is generally well tolerated.Hidaka et al., safety assessment of coenzyme Q10 (CoQ10)
No change in warfarin dose or INR with CoQ10 (36.5 vs 36.0 mg a week in 24 patients)
CoQ10 is structurally similar to vitamin K, which raised a theoretical concern that it could antagonize warfarin and lower the INR, supported by isolated case reports. Engelsen 2003 tested this directly: 24 outpatients on stable long-term warfarin received CoQ10 100 mg daily, ginkgo, or placebo in random order over four-week periods in a double-blind crossover, with warfarin adjusted to keep the INR between 2.0 and 4.0. The INR stayed stable throughout and the geometric mean weekly warfarin dose did not change (CoQ10 36.5 mg/week vs placebo 36.0 mg/week). The trial is small, so it cannot exclude a rare individual interaction, which is why alerting the clinician who manages an INR remains sensible even though the controlled evidence shows no effect.Engelsen et al., effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized, double-blind, placebo-controlled crossover trial
If you take warfarin, mention CoQ10 to whoever manages your dose
CoQ10 is structurally similar to vitamin K, and case reports describe it lowering the INR. A lower INR would make warfarin less effective at preventing clots. The one randomized crossover trial that tested this found no change in warfarin dose or INR, so the interaction is not established. If you take warfarin, tell whoever adjusts your dose that you are taking CoQ10 so your INR can be checked while you settle in.
Mild stomach upset at higher doses
CoQ10 is one of the better-tolerated supplements, and a formal safety review put the observed safe level around 1200 mg a day. The occasional complaints, nausea, loose stools or an upset stomach, cluster at higher doses and usually settle by taking it with food.
It does not replace a statin or a heart medicine
CoQ10 does not lower cholesterol, and it does not replace a statin, a blood-pressure drug, or any heart-failure medication. Dropping a prescribed medicine for CoQ10 trades away the treatment that carries the real evidence.
Limited data in pregnancy and breastfeeding
There is little safety research on CoQ10 during pregnancy or breastfeeding. That is not a signal of harm, only an absence of study. Raise it with your clinician before starting.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Will CoQ10 give me more energy if I am healthy but tired?
No trial shows a boost in healthy, non-deficient people. Everyday tiredness usually traces to sleep, stress, activity, and what you eat, where the return on effort is higher.
Does CoQ10 lower blood pressure?
Any effect from CoQ10 is small at most. An early review reported a noticeable drop. A later Cochrane review, keeping only the soundest randomized trials, found no meaningful change in systolic or diastolic pressure.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 14 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.